AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03617575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: holo-Lactoferrin
Description: 1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
Study NCT03617575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4
Description: 1.5 mg FeSO4 as 54Fe in a maize porridge
Study NCT03617575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1. FeSO4
Description: 10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
Study NCT03617575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4 after 1 day break
Description: 10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
Study NCT03617575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4 after 2 day break
Description: 10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
Study NCT02531633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match prednisone
Description: Placebo to match prednisone will be provided as tablets.
Study NCT02533037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Instability Tools
Description: Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
Study NCT02533037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle Destabilization Shoes
Description: Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
Study NCT01938378 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Octaplas™
Description: octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
Study NCT04684498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir phosphate capsules
Description: Treatment group vs. Control group
Study NCT00777400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: 1 mg/kg of efalizumab administered sub q once weekly
Study NCT03177447 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ENABLE CHF-PC
Description: An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
Study NCT01898949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Exposure
Description: Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
Study NCT00902421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Description: escitalopram 10mg once daily for 3 months
Study NCT00902421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimuscarinics
Description: Antimuscarinics for 3 months
Study NCT01386541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BYK324677
Description: capsules, administered orally
Study NCT01386541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BYK324677
Description: capsules, administered orally
Study NCT04289077 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: - Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
Study NCT00531297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic posterior mesorectal resection
Description: 6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
Study NCT02046850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
Study NCT02531633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match prednisone
Description: Placebo to match prednisone will be provided as tablets.
Study NCT02046850 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rifampicin
Description: Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
Study NCT02046850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
Study NCT02046850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
Study NCT00701636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
Study NCT00928278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Inhaled, 300/150, single dose
Study NCT00928278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Inhaled, 300/150, single dose
Study NCT04684498 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir phosphate capsules
Description: Treatment group vs. Control group
Study NCT01451359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBronchial Valve
Description: The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
Study NCT01726998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait therapy
Description: Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
Study NCT01726998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional gait training
Description: Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
Study NCT03083678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
Study NCT01051947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: 10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
Study NCT01051947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: dosage prescribed prior to starting on study
Study NCT04215276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Valsalva maneuver
Description: pressure during Valsalva maneuver was measure using sphygmomanometer
Study NCT04215276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: patient was not given any intervention
Study NCT05885620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drinking reminder and cognitive task (smartwatch-based application)
Description: task A: prompt to drink some water task B: prompt to circle bells on a sheet
Study NCT03849937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Changing Talk Online (CHATO)
Description: Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
Study NCT03849937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changing Talk Online (CHATO)
Description: Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
Study NCT03488459 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine preoperative information from a nurse
Description: Routine preoperative information from a nurse.
Study NCT03488459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional information support from a psychologist
Description: Routine preoperative information from a nurse + additional information support from a psychologist.
Study NCT00928278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Inhaled, 300/150, single dose + oral activated charcoal block
Study NCT00928278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment D
Description: Inhaled, 300/150, single dose + oral activated charcoal block
Study NCT00220805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
Description: The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
Study NCT00220805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin (Human) 25%, United States Pharmacopeia (USP)
Description: Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
Study NCT02045225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of social anxiety & substance use in gay/bi men
Description: The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
Study NCT04255316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified method of eversion carotid endarterectomy
Description: Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
Study NCT05122923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serious Game S'TIM
Description: Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
Study NCT01587638 — intervention group
Intervention type: DRUG
Intervention: carvedilol
Description: carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
Study NCT01587638 — intervention group
Intervention type: DRUG
Intervention: cardio selective betablocker
Description: atenolol, metoprolol succinate, and metoprolol tartrate
Study NCT03998748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Genetic Feedback
Description: Participants will be told either that they have or do not have a genetic predisposition to developing depression.
Study NCT03998748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Genetic Feedback
Description: Participants will be told either that they have or do not have a genetic predisposition to developing depression.
Study NCT04255316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard method of eversion carotid endarterectomy
Description: standard eversion technic
Study NCT01084525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104 (steroid) 3 mg
Description: OTO-104 3 mg dose cohort, single intratympanic injection.
Study NCT01084525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
Study NCT04573426 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen
Description: 1,000mg liquid acetaminophen
Study NCT04573426 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Liquid placebo solution
Study NCT04573426 — intervention group
Intervention type: BEHAVIORAL
Intervention: Weight stigma vignette
Description: Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
Study NCT04573426 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control vignette
Description: Short vignette meant to have no effect on emotion describing a generic promotion process
Study NCT01780285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol-framed lightweight PTFE mesh for hiatal repair
Description: The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair.
Study NCT02523768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-F
Study NCT01780285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partially absorbable lightweight mesh for hiatal repair
Description: A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure).
Study NCT03249480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: 30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
Study NCT02417129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: BI 695500 375 mg/M2
Study NCT02417129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500
Description: BI 695500 375 mg/M2
Study NCT04572724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
Study NCT04572724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAS Inhibitors
Description: RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
Study NCT01084525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104 (steroid) 12 mg
Description: Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
Study NCT01266369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Study NCT02523768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Study NCT01349270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin perfusion
Description: patient who received monthly 2g/kg intravenous cure of immunoglobulin
Study NCT02671149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will receive two cups of 150ml plain water
Study NCT01349270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
Study NCT01680562 — intervention group
Intervention type: OTHER
Intervention: in-vivo skin tumor imaging via optical coherence tomography
Description: optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
Study NCT04079322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal
Description: Participants will consume a meal containing a stable iron isotope following exercise or rest.
Study NCT03479840 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
Study NCT02596061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit Contract
Description: Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
Study NCT02596061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Patients receive incentives for completing smoking cessation activities.
Study NCT03181672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate ganglion block
Description: Stellate ganglion block with 1% lidocaine 10ml
Study NCT00597376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerefolin NAC (a medical food)
Description: Cerefolin NAC one tablet each day
Study NCT00597376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cerefolin NAC placebo
Description: Placebo tablet once a day
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Intravenous infusion of flucloxacillin sodium 1g an hour before operation
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. No routine bowel preparation;~2. Normal eating 1 days before the operation;~3. No drinking 2h and solid food 6h before the operation;~4. Drink 10% glucose 250ml 3h before operation ;~5. Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Emphasize the preoperative psychological preparation for patients.
Study NCT00989742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 50mg od
Study NCT00989742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg od
Study NCT00747006 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TI Inhalation Powder and Humalog (Amendment 1)
Description: Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
Study NCT00747006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI Inhalation Powder (original protocol)
Description: Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
Study NCT02479581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
Study NCT03181672 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Deltoid muscle injection with 1% lidocaine 10ml